1. Home
  2. CORT vs BIO Comparison

CORT vs BIO Comparison

Compare CORT & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$111.91

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

N/A

Current Price

$357.75

Market Cap

8.0B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CORT
BIO
Founded
1998
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.0B
IPO Year
2001
1994

Fundamental Metrics

Financial Performance
Metric
CORT
BIO
Price
$111.91
$357.75
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$96.50
$339.75
AVG Volume (30 Days)
1.3M
297.8K
Earning Date
04-30-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
142.61
EPS
0.09
N/A
Revenue
$761,407,000.00
$2,583,200,000.00
Revenue This Year
$26.08
$2.74
Revenue Next Year
$26.98
$3.20
P/E Ratio
$1,267.14
$9.72
Revenue Growth
12.79
0.65
52 Week Low
$28.66
$236.73
52 Week High
$122.21
$355.85

Technical Indicators

Market Signals
Indicator
CORT
BIO
Relative Strength Index (RSI) 65.59 74.55
Support Level $76.41 $290.67
Resistance Level $122.21 N/A
Average True Range (ATR) 5.21 11.43
MACD 0.55 2.87
Stochastic Oscillator 72.40 97.11

Price Performance

Historical Comparison
CORT
BIO

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: